Our Science
Publications & Presentations
Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
-
Durable Disease Control with Obexelimab in IgG4-Related Disease: Phase 3 INDIGO Open-Label Extension
ACR Convergence 2026 -
Clinically Meaningful Influenza and SARS-CoV-2 Vaccine Responses Following Treatment-Free Window of Obexelimab in Patients with IgG4-RD
ACR Convergence 2026 -
Effect of Obexelimab on Serum Biomarkers and MS Disease Activity Score: Results from the Phase 2 MoonStone Trial in Relapsing Multiple Sclerosis
ACTRIMS-ECTRIMS Meeting (MSToronto2026) -
Obexelimab Demonstrated Reduction in Disease Activity in Relapsing Multiple Sclerosis: 24-Week Results from the MoonStone Phase 2 Trial
ACTRIMS-ECTRIMS Meeting (MSToronto2026) -
Pharmacokinetics and Pharmacodynamics of Obexelimab in Patients with Relapsing Multiple Sclerosis: Results from the Phase 2 MoonStone Trial
ACTRIMS-ECTRIMS Meeting (MSToronto2026) -
Obexelimab, a B Cell Inhibitor, in IgG4-Related Disease: Results From the Phase 3 INDIGO Trial
European Alliance of Associations for Rheumatology (EULAR) 2026 Congress -
Obexelimab for the Treatment of IgG4-Related Disease
New England Journal of Medicine
Orelabrutinib
-
Efficacy and Safety of Orelabrutinib in Relapsing-Remitting Multiple Sclerosis: 24-Week Results of the 80 mg Dose from a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
ACTRIMS-ECTRIMS Meeting (MSToronto2026) -
Orelabrutinib in Non-Active Secondary Progressive Multiple Sclerosis: Design of the Monarch Phase 3 Randomized Controlled Trial
ACTRIMS-ECTRIMS Meeting (MSToronto2026) -
Orelabrutinib in Primary Progressive Multiple Sclerosis: Design of the PriMroSe Phase 3 Randomized Controlled Trial
ACTRIMS-ECTRIMS Meeting (MSToronto2026) -
Pharmacokinetics of Orelabrutinib in a Phase 2 Study in Relapsing Remitting Multiple Sclerosis
ACTRIMS-ECTRIMS Meeting (MSToronto2026)
